The jumbo leveraged buyout is attempting a comeback. A deal for Sanofi SA’s consumer health-care business — purveyor of laxative brand Dulcolax — would be the perfect remedy for private equity’s constipation.

Advent International, Bain Capital, Blackstone Inc., CVC Capital Partners, EQT AB and KKR & Co. are mulling offers to relieve the French pharmaceutical firm of the division at a possible $20 billion valuation, Bloomberg News reported last week. Sanofi has said it plans to separate the unit, most likely by giving it a separate listing. You can see why so many buyout shops are hoping for an outright sale instead.

QOSHE - A $20 Billion Deal Would Relieve LBO Constipation - Chris Hughes
menu_open
Columnists Actual . Favourites . Archive
We use cookies to provide some features and experiences in QOSHE

More information  .  Close
Aa Aa Aa
- A +

A $20 Billion Deal Would Relieve LBO Constipation

3 5
26.02.2024

The jumbo leveraged buyout is attempting a comeback. A deal for Sanofi SA’s consumer health-care business — purveyor of laxative brand Dulcolax —........

© Bloomberg

Get it on Google Play